Ardelyx extends losses

Ardelyx Inc. (Nasdaq: ARDX) reported positive preclinical data for tenapanor in treating abdominal pain caused by irritable bowel syndrome with constipation but the stock price continued to fall by losing 88 cents to close at $$6.40 as investors locked in profits.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.